These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 37344)

  • 41. Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells.
    Babudri N; Pani B; Tamaro M; Monti-Bragadin C; Zunino F
    Br J Cancer; 1984 Jul; 50(1):91-6. PubMed ID: 6378238
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intercalation and induction of strand breaks by adriamycin and daunomycin: a study with human genomic DNA.
    Ghosh D; Hossain M; Saha C; Dey SK; Kumar GS
    DNA Cell Biol; 2012 Mar; 31(3):378-87. PubMed ID: 21848427
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of nitroso chemical carcinogen activation of rat hepatic guanylate cyclase by anticancer agents.
    Vesely DL; Levey GS
    Oncology; 1979; 36(3):122-6. PubMed ID: 38420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A sensitive method for the assay of guanylate cyclase activity.
    Karczewski P; Krause EG
    Acta Biol Med Ger; 1978; 37(7):961-7. PubMed ID: 34307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice.
    Vandenwijngaert S; Swinnen M; Walravens AS; Beerens M; Gillijns H; Caluwé E; Tainsh RE; Nathan DI; Allen K; Brouckaert P; Bartunek J; Scherrer-Crosbie M; Bloch KD; Bloch DB; Janssens SP; Buys ES
    Antioxid Redox Signal; 2017 Feb; 26(4):153-164. PubMed ID: 27505125
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro studies on anthracycline haloderivatives.
    Facchinetti T; Geroni C; Fumagalli A; Giuliani FC
    Drugs Exp Clin Res; 1986; 12(8):657-61. PubMed ID: 3463498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of guanylate cyclases by methylxanthines and papaverine.
    Strinden ST; Stellwagen RH
    Biochem Biophys Res Commun; 1984 Sep; 123(3):1194-200. PubMed ID: 6207821
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.
    Schott B; Robert J
    Biochem Pharmacol; 1989 Nov; 38(22):4069-74. PubMed ID: 2597184
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity.
    Hori S; Shirai M; Hirano S; Oki T; Inui T; Tsukagoshi S; Ishizuka M; Takeuchi T; Umezawa H
    Gan; 1977 Oct; 68(5):685-90. PubMed ID: 579346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiac sodium, potassium-adenosine triphosphatase as a possible site of adriamycin-induced cardiotoxicity.
    Solomonson LP; Halabrin PR
    Cancer Res; 1981 Feb; 41(2):570-2. PubMed ID: 6256069
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Daunorubicin therapy is associated with upregulation of E3 ubiquitin ligases in the heart.
    Sishi BJ; Bester DJ; Wergeland A; Loos B; Jonassen AK; van Rooyen J; Engelbrecht AM
    Exp Biol Med (Maywood); 2012 Feb; 237(2):219-26. PubMed ID: 22328594
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibitory effects of anthracenedione antineoplastic agents on hepatic and cardiac lipid peroxidation.
    Kharasch ED; Novak RF
    J Pharmacol Exp Ther; 1983 Aug; 226(2):500-6. PubMed ID: 6875860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.
    Dziegiel P; Jethon Z; Suder E; Sopel M; Rabczyński J; Surowiak P; Zabel M
    Exp Toxicol Pathol; 2002 Feb; 53(6):433-9. PubMed ID: 11926284
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Cross resistance in tumor cells and staphylococci with respect to anthracycline-group antineoplastic antibiotics].
    Shorin VA; Averbukh LA
    Antibiotiki; 1976 Oct; 21(10):914-9. PubMed ID: 999240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of the structure of new anthracycline antibiotics on their biological properties.
    Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
    Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
    Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
    Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative mammalian metabolism of adriamycin and daunorubicin.
    Loveless H; Arena E; Felsted RL; Bachur NR
    Cancer Res; 1978 Mar; 38(3):593-8. PubMed ID: 626965
    [No Abstract]   [Full Text] [Related]  

  • 59. Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review.
    Aubel-Sadron G; Londos-Gagliardi D
    Biochimie; 1984 May; 66(5):333-52. PubMed ID: 6380596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
    Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
    Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.